Allergy最新文献

{"title":"Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma","authors":"Michael E. Wechsler,&nbsp;Sally E. Wenzel,&nbsp;Steve D. Groshong,&nbsp;Mario Castro,&nbsp;Ian D. Pavord,&nbsp;Klaus F. Rabe,&nbsp;Elizabeth Laws,&nbsp;Alexandre Jagerschmidt,&nbsp;Kaitlyn Gayvert,&nbsp;Sivan Harel,&nbsp;Jennifer D. Hamilton,&nbsp;Nikhil Amin,&nbsp;Lu Zhang,&nbsp;Heming Xing,&nbsp;Anissa Elfakir,&nbsp;Bema Coulibaly,&nbsp;Souâd Naimi,&nbsp;Sara Hamon,&nbsp;Paul J. Rowe,&nbsp;Frank Nestle,&nbsp;Danen M. Cunoosamy,&nbsp;Emanuele de Rinaldis,&nbsp;Leda P. Mannent","doi":"10.1111/all.70391","DOIUrl":"10.1111/all.70391","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Biologics targeting type 2 cytokines can inhibit airway inflammation and improve lung function in moderate-to-severe asthma; however, their impact on airway mucosal inflammatory cells is unclear. This study assessed the effects of dupilumab on airway mucosal and systemic inflammation, and related gene expression in patients with persistent asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In the phase 2a EXPEDITION study (NCT02573233), patients aged 18–65 years were randomised to add-on dupilumab 300 mg (<i>n</i> = 20) or placebo (<i>n</i> = 22) every 2 weeks for 12 weeks. Pre- and post-treatment bronchial biopsies, bronchial brushings, bronchoalveolar lavage (BAL) fluid and blood samples were collected. Clinical and patient-reported outcomes, gene expression, type 2 biomarkers and safety outcomes were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Dupilumab versus placebo improved lung function and asthma control. No significant changes in eosinophils, mast cells or type 2 helper cells were observed in bronchial biopsies. Downregulation of <i>M2 macrophage-</i> and <i>eosinophil</i>-associated gene sets was observed in BAL and brushing samples after dupilumab. Dupilumab decreased multiple circulating type 2 biomarkers in peripheral blood (<i>p</i>_unadj &lt; 0.001, <i>p</i>_adj &lt; 0.01), goblet cell numbers (<i>p</i>_unadj = 0.0336; <i>p</i>_adj = 0.2554) and mucus area (<i>p</i>_unadj = 0.0426; <i>p</i>_adj = 0.2554) in bronchial biopsies versus placebo. The safety profile was consistent with the known safety profile of dupilumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Dupilumab improved lung function and asthma control while reducing circulating type 2 biomarkers. No measurable impact was observed on type 2-associated inflammatory cell numbers in airway bronchial biopsies; however, dupilumab modulated the expression of inflammation-associated gene sets. These findings provide cellular and molecular data that may explain dupilumab-driven mechanisms of improved lung function in patients with type 2 asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"81 9","pages":"3261-3272"},"PeriodicalIF":11.3,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.70391","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148050932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial","authors":"Michael E. Wechsler, Praveen Akuthota, Barry Quart, Raúl Collazo","doi":"10.1111/all.70506","DOIUrl":"https://doi.org/10.1111/all.70506","url":null,"abstract":"Background Rademikibart, an IL‐4Rα‐targeting antibody, demonstrated efficacy in a Phase 2b trial of adults with moderate‐to‐severe uncontrolled asthma (NCT04773678). We report exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count (EOS) and fractional exhaled nitric oxide (FeNO). Methods Patients were randomized, double‐blind, to rademikibart 150 mg or 300 mg Q2W (600‐mg loading) or placebo, with medium‐to‐high dose inhaled corticosteroids and ≥ 1 reliever/controller. Up to eight EOS/FeNO subgroups were investigated, focusing on the following five: ≥ 300 cells/μL and ≥ 25 ppb ( <jats:italic>N</jats:italic> = 80); ≥ 25 ppb ( <jats:italic>N</jats:italic> = 142); ≥ 300 cells/μL ( <jats:italic>N</jats:italic> = 129); ≥ 150 cells/μL ( <jats:italic>N</jats:italic> = 247); 150– &lt; 300 cells/μL ( <jats:italic>N</jats:italic> = 118). Results Prebronchodilator FEV <jats:sub>1</jats:sub> increased significantly at first assessment (Week 1) and was sustained throughout the 24‐week treatment period. FEV <jats:sub>1</jats:sub> and asthma control (ACQ‐6) improvements were greatest when baseline EOS and FeNO were both elevated. At Week 1, after a 600‐mg loading dose, placebo‐adjusted FEV <jats:sub>1</jats:sub> increased by 422 mL (≥ 300 cells/μL and ≥ 25 ppb), 339 mL (≥ 25 ppb), 324 mL (≥ 300 cells/μL), 227 mL (≥ 150 cells/μL), and 141 mL (150– &lt; 300 cells/μL). At Week 24, with 300 mg Q2W, placebo‐adjusted FEV <jats:sub>1</jats:sub> increased by 519 mL (≥ 300 cells/μL and ≥ 25 ppb), 401 mL (≥ 25 ppb), 394 mL (≥ 300 cells/μL), 287 mL (≥ 150 cells/μL), and 159 mL (150– &lt; 300 cells/μL). Exacerbations decreased by ≥ 63% per subgroup. Rademikibart was well tolerated. No eosinophilia (Preferred Term) was reported. Grade 1 eosinophil count increased did not lead to treatment discontinuation ( <jats:italic>n</jats:italic> = 2). Conclusions Rapid and sustained improvements were more pronounced in patients with type 2‐high biomarkers than previously reported in the overall study population.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"1 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148915459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"As‐Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK ‐air Study","authors":"Bernardo Sousa‐Pinto, Rafael José Vieira, Antonio Bognanni, Ludger Klimek, Ana Margarida Pereira, Rita Amaral, Anna Bedbrook, Patrizia Bonadonna, Luisa Brussino, Mark S. Dykewicz, Mattia Giovannini, Bilun Gemicioglu, Juan Carlos Ivancevich, Violeta Kvedariene, Manuel Marques‐Cruz, Matteo Martini, André Moreira, Marek Niedoszytko, Michal Ordak, Nikolaos G. Papadopoulos, Oliver Pfaar, Nhân Pham‐Thi, Orathai Jirapongsananuruk, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Joaquin Sastre, Luís Taborda‐Barata, Ilgım Vardaloğlu Koyuncu, Arunas Valiulis, Maria Teresa Ventura, Kangsadarn Tanjararak, Yi‐Kui Xiang, Mohamed H. Shamji, Maria José Torres, Holger J. Schünemann, Danilo di Bona, João A. Fonseca, Torsten Zuberbier, Jean Bousquet","doi":"10.1111/all.70508","DOIUrl":"https://doi.org/10.1111/all.70508","url":null,"abstract":"Background Patients with allergic rhinitis often use as‐needed medication instead of regular treatment. Using data from the MASK‐air mHealth app, we compared weeks with use of as‐needed versus regular medication on treatment satisfaction and symptom control. Methods We assessed data from the MASK‐air app. We compared weeks in the pollen season in which patients reported the use of one same medication during all the days in the week (“regular treatment”) versus those in which patients reported the use of the same single medication (and no other treatments) in at most 4 days per week (“as‐needed treatment”). We built mixed‐effects linear regression models, evaluating the differences between regular and as‐needed treatments on visual analogue scales for symptom control and treatment satisfaction. We performed sensitivity analyses (i) considering a different definition of as‐needed treatment (use of medication ≤ 2 days per week), and (ii) evaluating treatment days preceded by non‐treatment days. Results We assessed 2690 weeks (18,830 days, 1042 MASK‐air users). For intranasal corticosteroids (INCS) and fixed combinations of intranasal antihistamines (INAH) + INCS, there were no significant differences between as‐needed versus regular treatments for treatment satisfaction. For oral antihistamines (OAH) and INCS + OAH, results tended to favour as‐needed approaches. For symptom control, we observed either no significant differences between the two approaches or significant differences favouring as‐needed medication use. Similar results were found in the sensitivity analyses. Conclusion Some patients use medication regularly and others use it on‐demand. This study shows that both approaches can satisfy patients and result in good disease control.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"19 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148909157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases","authors":"Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis","doi":"10.1111/all.70512","DOIUrl":"https://doi.org/10.1111/all.70512","url":null,"abstract":"Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue protection and repair. There are major clues from the early evolution of T2 responses for protection against massive tissue damage and positive selection for survival against parasites starting over 500 million years ago. These responses likely co‐evolved stepwise with immune‐regulatory circuits, culminating in the emergence of the fully functional human‐type IgG4 in the great apes (Hominidae) within the last ~10 million years. The involvement of body barriers along with the strong influence of local epithelial cells and their interaction with the microbiome and the immune system is a common characteristic of T2 inflammation. An expanding list of new T2 diseases is being reported, characterized by epithelial cell and immune system activation, epithelial barrier damage, and microbial dysbiosis, including opportunistic pathogen colonization and loss of commensals. This evolving understanding coincides with the clinical success of biologics targeting key T2 mediators such as IL‐4, IL‐5, IL‐13, IL‐31, TSLP, and IgE, which have transformed the management of severe allergic diseases and other T2‐driven pathologies. However, the contribution of T2 immunity to homeostatic programs raises questions about the long‐term consequences of sustained T2 suppression. In this review, we examine the dual role of T2 immunity in health and disease, revisit its evolutionary origins, highlight its protective functions beyond allergy, and discuss the potential implications of prolonged T2 pathway blockade.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"154 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148909163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma Remission From Childhood to Young Adulthood-A Population-Based Cohort Study.","authors":"Lina Broström, Anna Bergström, Anne-Sophie Merritt, Maria Ödling, Erik Melén, Inger Kull, Sandra Ekström","doi":"10.1111/all.70496","DOIUrl":"https://doi.org/10.1111/all.70496","url":null,"abstract":"<p><strong>Background: </strong>The long-term prognosis of childhood asthma remains uncertain. We aimed to (1) assess the prevalence of asthma remission from childhood to young adulthood, (2) identify associated factors, and (3) evaluate whether symptom-based remission was related to objective markers of inflammation and lung function.</p><p><strong>Materials and methods: </strong>We analyzed data from 2698 participants in the Swedish population-based BAMSE birth cohort, followed up to age 24 years with questionnaires and clinical examinations. Symptom-based remission was defined as absence of asthma symptoms and medication in the preceding year. Clinical remission also required no hospital visits and optimization of lung function (postbronchodilator forced expiratory volume in 1 s ≥ 80%). Complete remission required normal eosinophil counts (< 0.3 × 10⁹/L) and fractional exhaled nitric oxide levels (< 40 ppb).</p><p><strong>Results: </strong>Among 257 participants with asthma at age 8 years, 39% achieved symptom-based remission, 29% clinical remission, and 18% complete remission at age 24 years. Male sex increased the likelihood of symptom-based remission (odds ratio [OR] 2.4, 95% confidence interval [CI] 1.3-4.5), whereas food sensitization (OR 0.3, 95% CI 0.3-0.6) and overweight/obesity (OR 0.4, 95% CI 0.2-0.9) decreased it. Among individuals in symptom-based remission, 27% displayed abnormal results in at least one objective marker.</p><p><strong>Conclusions: </strong>Four of 10 participants with asthma in childhood achieved symptom-based remission by young adulthood, but rates declined when stricter, objective definitions were applied. A substantial subset of individuals with symptom-based remission still showed signs of type two inflammation or reduced lung function, indicating that absence of symptoms does not necessarily reflect complete disease resolution.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":11.3,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148899785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Local Delivery of a Bio‐Engineered IL ‐37 Fc‐Fusion Ameliorates Experimental Allergic Asthma in Mice","authors":"Lars P. Lunding, Marcel F. Nold, Claudia A. Nold‐Petry, Michael Wegmann","doi":"10.1111/all.70509","DOIUrl":"https://doi.org/10.1111/all.70509","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"5 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy","authors":"Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova","doi":"10.1111/all.70504","DOIUrl":"https://doi.org/10.1111/all.70504","url":null,"abstract":"Background We have recently reported the preclinical characterization of a recombinant birch pollen allergy vaccine based on a fusion protein, &lt;jats:styled-content style=\"fixed-case\"&gt;AB&lt;/jats:styled-content&gt; ‐ &lt;jats:styled-content style=\"fixed-case\"&gt;PreS&lt;/jats:styled-content&gt; , consisting of allergen‐derived peptides fused to the hepatitis B virus ( &lt;jats:styled-content style=\"fixed-case\"&gt;HBV&lt;/jats:styled-content&gt; )‐derived &lt;jats:styled-content style=\"fixed-case\"&gt;PreS&lt;/jats:styled-content&gt; surface protein as immunological carrier. Objective To investigate in a clinical study the usefulness of the &lt;jats:styled-content style=\"fixed-case\"&gt;AB&lt;/jats:styled-content&gt; ‐ &lt;jats:styled-content style=\"fixed-case\"&gt;PreS&lt;/jats:styled-content&gt; vaccine, termed &lt;jats:styled-content style=\"fixed-case\"&gt;GNR&lt;/jats:styled-content&gt; ‐127, for allergen‐specific immunotherapy of birch pollen allergy. Methods Stage 1 of the study, an open‐label Phase I study, determined among three doses (20 μg: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 6; 40 μg: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 6; 80 μg: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 6) administered as Aluminum‐hydroxide‐adsorbed vaccines subcutaneously five times in monthly intervals, the highest tolerated doses. In the following Stage 2, randomized patients (placebo: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 45; 40 μg: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 43; 80 μg: &lt;jats:italic&gt;n&lt;/jats:italic&gt; = 44) received in a single‐blind, placebo‐controlled Phase II study monthly up to five pre‐seasonal injections. Safety monitoring followed the Medical Dictionary for Regulatory Activities (MedDRA); efficacy parameters were determined according to the European Academy for Allergy and Clinical Immunology ( &lt;jats:styled-content style=\"fixed-case\"&gt;EAACI&lt;/jats:styled-content&gt; ) guidelines; allergen‐specific antibodies and basophil sensitivity were determined by &lt;jats:styled-content style=\"fixed-case\"&gt;ELISA&lt;/jats:styled-content&gt; and basophil activation testing, respectively. Results A dose‐dependent reduction of the combined symptom medication score ( &lt;jats:styled-content style=\"fixed-case\"&gt;CSMS&lt;/jats:styled-content&gt; ) (40 μg: 17.41%; 80 μg: 24.13%) over placebo was observed which was significant for the 80 μg group and accompanied by the strongest induction of Bet v 1‐specific &lt;jats:styled-content style=\"fixed-case\"&gt;IgG&lt;/jats:styled-content&gt; (median 20‐fold increase) and a blunting of the seasonally boosted &lt;jats:styled-content style=\"fixed-case\"&gt;IgE&lt;/jats:styled-content&gt; response and basophil sensitivity. The vaccine showed an acceptable safety profile despite high administered doses. Conclusion A pre‐seasonal course of 5 monthly injections of &lt;jats:styled-content style=\"fixed-case\"&gt;GNR&lt;/jats:styled-content&gt; ‐127 80 μg improved symptoms of birch pollen allergy accompanied by a robust Bet v 1‐specific &lt;jats:styled-content style=\"fixed-case\"&gt;IgG&lt;/jats:styled-content&gt; response, paving the road for a Phase III efficacy study. Trial Registration &lt;jats:ext-link xmlns:xlink=\"http://www.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"16 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate‐to‐Severe Atopic Dermatitis","authors":"Daniel Liu, Ester Del Duca, Nicolas Delaleu, Megan Lau, Juliana Pulsinelli, Joel Correa de Rosa, Jonathan Bar, Yeriel Estrada, Johann Gudjonsson, Valerie Julia, Emma Guttman‐Yassky","doi":"10.1111/all.70505","DOIUrl":"https://doi.org/10.1111/all.70505","url":null,"abstract":"Background Atopic dermatitis (AD) is characterized by pruritus, epidermal hyperplasia, and lichenification that significantly impairs quality of life. Nemolizumab, an anti–IL‐31Rα monoclonal antibody, is approved for treating moderate‐to‐severe AD in patients aged &gt; 12 years. This study investigated nemolizumab's molecular mechanisms using patient samples from the ARCADIA 1 (NCT03985943) and 2 (NCT03989349) trials. Methods Tape‐strips were collected from the lesional and non‐lesional skin of 71 nemolizumab‐treated and 39 placebo‐treated patients, all receiving background topical corticosteroids ± topical calcineurin inhibitors, at baseline and after 16 weeks of treatment for bulk RNAseq analysis. Single cell RNAseq was performed on a subset of untreated patients and used as a reference to map bulk RNA‐seq DEGs, providing cellular context for treatment‐associated transcriptional changes. Results Bulk RNAseq revealed significant transcriptomic modulation following 16 weeks of nemolizumab treatment (797 downregulated/142 upregulated genes), while placebo‐treated patients showed minimal changes. Nemolizumab treatment attenuated expression of pruritus‐related genes (e.g., <jats:italic>OSMR</jats:italic> , <jats:italic>TRPV3</jats:italic> , <jats:italic>HRH1</jats:italic> , <jats:italic>KLK6/7/9</jats:italic> ) and genes involved in epidermal hyperplasia and ECM remodeling (e.g., <jats:italic>COL1A1/12A1</jats:italic> , <jats:italic>IGFBP3</jats:italic> ). Inflammatory pathways were also modulated, with downregulation of Th17‐ and Th1‐related genes (e.g., <jats:italic>S100A7/8/9</jats:italic> , <jats:italic>PI3</jats:italic> , <jats:italic>MX1</jats:italic> , <jats:italic>OASL</jats:italic> ). Pathway‐level analysis demonstrated normalization of pruritus and inflammatory gene signatures, including Th2 and Th22 pathways. Subgroup analysis showed that patients with severe baseline pruritus (PPNRS ≥ 7) had higher baseline expression of immune‐related genes and experienced greater downregulation following treatment compared to patients with moderate baseline itch. Single‐cell mapping of differentially expressed genes suggested enrichment of these genes in keratinocyte, fibroblast, endothelial, and nerve cell subpopulations. Clinically, improvements in EASI and pruritus scores (PPNRS) correlated with decreased expression of fibrosis‐ and pruritus‐associated genes. Conclusion Our findings provide molecular evidence supporting nemolizumab's therapeutic efficacy across multiple disease domains, including pruritus, inflammation, and epidermal hyperplasia, highlighting its role in AD treatment and management.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"4 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classification of Seasonal Allergic Rhinitis Patients by Prospective Patient-Recorded Symptoms: The @IT.2020 Project.","authors":"Stephanie Dramburg, Camilo J Hernandez Toro, Ulrike Grittner, Ekaterina Potapova, Alessandro Travaglini, Salvatore Tripodi, Stefania Arasi, Simone Pelosi, Francesco Monnati, Aydan Acar Şahin, Xenophon Aggelidis, Andrea Barbalace, Anne Bourgoin, Blerina Bregu, Maria Antonia Brighetti, Elsa Caeiro, Sule Caglayan Sozmen, Lucia Caminiti, Denis Charpin, Mariana Couto, Luís Delgado, Andrea Di Rienzo Businco, Claire Dimier, Maria V Dimou, João A Fonseca, Ozlem Goksel, Dolores Hernandez, Tara Maria Hoffmann, Dah Tay Jang, Fusun Kalpaklioglu, Blerta Lame, Ruth Llusar, Michael P Makris, Angel Mazon, Eris Mesonjesi, Antonio Nieto, Ayse Bilge Öztürk, Laurie Pahus, Giovanni Battista Pajno, Ilenia Panasiti, Nikolaos G Papadopoulos, Elisabetta Pellegrini, Ana Margarida Pereira, Mariana Pereira, Munevver Pinar, Alfred Priftanji, Fotis Psarros, Cansin Sackesen, Ifigenia Sfika, Javier Suarez, Michel Thibaudon, Ulas Uguz, Valentine Verdier, Valeria Villella, Paraskevi Xepapadaki, Duygu Yazici, Paolo M Matricardi","doi":"10.1111/all.70447","DOIUrl":"10.1111/all.70447","url":null,"abstract":"<p><strong>Background: </strong>Seasonal allergic rhinitis (SAR) has been so far classified according to frequency and severity by retrospective information based on the ARIA (Allergic Rhinitis and its Impact on Asthma) classification. Electronic symptom diaries (e-Diaries) are feasible tools to collect prospective patient-reported data.</p><p><strong>Objective: </strong>To test the consistency between prospectively recorded symptoms and retrospective ARIA classification and to generate a new SAR classification based on prospective e-Diary data.</p><p><strong>Methods: </strong>Within the @IT.2020 multicentre observational study, we recruited 815 children and adults with SAR in nine study centres from Mediterranean countries. Participants recorded daily organ-specific (Rhinoconjunctivitis Total Symptom Score; RTSS) and general symptoms (visual analogue scale, VAS) plus quality-of-life measures via an e-Diary app. Retrospective clinical questionnaires were performed at the beginning (T0) and end (T1) of the pollen season. Unsupervised clustering analyses around medoids were implemented to classify SAR by prospective patient-reported data.</p><p><strong>Results: </strong>One third (56/164, 34.1%) and almost half (173/366, 47.3%) of the patients retrospectively over- or underestimated the frequency of their symptoms, respectively. A moderate correlation was found between SAR severity reported at T1 and prospectively recorded symptom severity. An unsupervised clustering approach was able to identify distinct groups (mild, moderate, severe cluster) of patients based on the prospective severity of organ-specific (RTSS) and overall symptoms (VAS), as well as quality of life criteria.</p><p><strong>Conclusions: </strong>A significant recall bias regarding frequency and severity of symptoms emerged by comparing the retrospective ARIA classification with prospectively recorded data by an e-Diary. A prospective approach to SAR classification, inspired by the retrospective ARIA classification, may facilitate a more precise evaluation of the patient for improved disease management.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":11.3,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moesin, a Cytoskeletal-Associated Protein, Outperforms Candidate Biomarkers in Identifying Asthma Exacerbation.","authors":"Pureun-Haneul Lee, SangMin Yoon, Cheolgi Lee, An-Soo Jang","doi":"10.1111/all.70389","DOIUrl":"10.1111/all.70389","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":"3384-3386"},"PeriodicalIF":11.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13569617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147872801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}